Pituitary: Acromegaly and Prolactinoma

FP27-3

Inhibition of GH and IGF-1 Is Maintained with Pasireotide LAR and Octreotide LAR in Patients with Acromegaly: 12-Month Extension Phase of a Double-Blind, Multicenter, Randomized, Phase III Study
Michael C Sheppard, Marcello D Bronstein, Pamela U. Freda, Omar Serri, Laura De Marinis, Luciana Ansaneli Naves, Liudmila Ya Rozhinskaya, Karina Hermosillo Reséndiz, Matthieu Ruffin, Kobby Asubonteng and Annamaria Colao

FP27-4

Pasireotide LAR and Octreotide LAR Normalize Prolactin Levels in Patients with Acromegaly and Hyperprolactinemia: Results from a Randomized, Double-Blind, 12-Month, Phase III Study
Annamaria Colao, Marcello D Bronstein, Feng Gu, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen and Pamela U. Freda

FP27-6

Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study
Kim M.J.A. Claessen, Alberto M. Pereira, Natasha M Appelman-Dijkstra, Neveen A.T. Hamdy, Herman Kroon, Margreet Kloppenburg and Nienke R. Biermasz